 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|
|
Directors Paul Berg, Ph.D. 2) Cahill Professor in Cancer Research and Biochemistry, Emeritus Director, Beckman Center, Emeritus Stanford University Medical Center John D. Diekman, Ph.D. 1) 3) Managing Director Bay City Capital Stephen P.A. Fodor, Ph.D. 1) Chairman and Chief Executive Officer Affymetrix, Inc. Vernon R. Loucks, Jr. 3) Chairman InLight, Inc. Former Chairman and Chief Executive Officer Baxter International Inc. David B. Singer 3) Chairman and Chief Executive Officer GeneSoft, Inc. Lubert Stryer, M.D. Winzer Professor in the School of Medicine Stanford University John A. Young 1) 2) President and Chief Executive Officer (Retired) Hewlett-Packard Company 1) Nominating Committee 2) Compensation Committee 3) Audit Committee Founding Director Emeritus |
Executive Officers Stephen P.A. Fodor, Ph.D. Chairman and Chief Executive Officer Edward M. Hurwitz Senior Vice President and Chief Financial Officer Vern Norviel Senior Vice President, General Counsel and Corporate Secretary Susan E. Siegel President Ronald D. Verdoorn Executive Vice President of Global Operations |
| Stock Market Information The Company’s Common Stock trades on The Nasdaq Stock Market® under the symbol AFFX. As of December 31, 2000 there were approximately 415 holders of record of the Company’s Common Stock. The table listed below reflects the high and low bid prices for 2000 and 1999. Per share prices have been adjusted to reflect the August 21, 2000 stock split.
Corporate Headquarters
All statements in this annual report that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, personnel retention, equity dilution, uncertainties related to the ability to realize benefits from acquisitions, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2000 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip® and the Affymetrix logo are registered trademarks used by Affymetrix, Inc. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||